H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIU – Research Report) on June 17 and set a price target of $16.00. The company's shares closed last Friday at $2.60, close to its 52-week low of $2.06. According to TipRanks.com, Fein 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.0% and a 26.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-ac-immune-sa-aciu?utm_source=advfn.com&utm_medium=referral